Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCS-PHC neoadjuvant chemotherapy in locally advanced perihilar cholangiocarcinoma
jRCTs041210063Phase 2Recruiting
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin and tegafur in hilar cholangiocarcinoma (HC). Primary endpoint: High responder rate after GCS therapy. Started Sep 2021; status: recruiting.
02
Drugs
gemcitabinecisplatintegafur
03
Conditions
hilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on jRCTs041210063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210063.